Johnson & Johnson’s COVID-19 vaccine is effective against the Delta variant, the company announced. The vaccine, which has been administered to some 11 million Americans, protects against the variant even eight months after inoculation. (The New York Times)
The Biden administration has launched surge response teams to target the new contagious Delta variant. This includes sending extra resources and expertise to “hot spots” where the virus is spreading in an attempt to curb further outbreaks in low vaccination areas. (The Washington Post)
Researchers have developed a battery-free pacemaker that can be absorbed by the body, according to a new study. The latest device could help overcome challenges associated with traditional permanent pacemakers, such as the risk of infection. (STAT)
GlaxoSmithKline is spending $700 million to partner with San Francisco biotech Alector to work on neurodegenerative disease antibodies. The return to neuroscience comes four years after GSK closed its neuro R&D hub in Shanghai. (Endpoints News)
Hospitals are now required to post their prices after a Trump administration price transparency rule that took effect in January. But some hospitals are burying the data on their websites or leaving some prices unclear. (Kaiser Health News)
